337 related articles for article (PubMed ID: 10626831)
1. Liver granulomatosis is not an exceptional cause of hypercalcemia with hypoparathyroidism in dialysis patients.
Hardy P; Morinière PH; Tribout B; Hamdini N; Marié A; Bouffandeau B; Pruna A; Fournier A
J Nephrol; 1999; 12(6):398-403. PubMed ID: 10626831
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid hormone changes during phosphorus load in patients with chronic renal insufficiency with low serum parathyroid hormone or adynamic bone disease.
Cuppari L; Carvalho AB; Lobão RR; Martini LA; Cendoroglo M; Ventura RT; Draibe SA
Clin Nephrol; 2001 Jul; 56(1):35-43. PubMed ID: 11499657
[TBL] [Abstract][Full Text] [Related]
5. Hypercalcemia as a result of sarcoidosis with normal serum concentrations of vitamin D.
Falk S; Kratzsch J; Paschke R; Koch CA
Med Sci Monit; 2007 Nov; 13(11):CS133-136. PubMed ID: 17968303
[TBL] [Abstract][Full Text] [Related]
6. Use of alkaline calcium salts as phosphate binder in uremic patients.
Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
[TBL] [Abstract][Full Text] [Related]
7. [Renal osteodystrophy (3); its treatment in dialysis patients].
Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
[TBL] [Abstract][Full Text] [Related]
8. [Hemodialysis with 2.5 mEq/L of calcium in relative hypoparathyroidism: long-term effects on bone mass].
Sánchez Perales MC; García Cortés MJ; Borrego FJ; Fernández Martínez S; Borrego J; Pérez del Barrio P; Liébana A; Pérez Bañasco V
Nefrologia; 2000; 20(3):254-61. PubMed ID: 10917002
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
[TBL] [Abstract][Full Text] [Related]
10. Idiopathic calcitriol-induced hypercalcemia. A new disease entity?
Evron E; Goland S; von der Walde J; Schattner A; Sthoeger ZM
Arch Intern Med; 1997 Oct; 157(18):2142-5. PubMed ID: 9382671
[TBL] [Abstract][Full Text] [Related]
11. [Association of hypercalcemia, elevated levels of calcitriol and tuberculosis in patients on hemodialysis].
Peces R; Díaz Corte C
Nefrologia; 2000; 20(5):448-54. PubMed ID: 11100667
[TBL] [Abstract][Full Text] [Related]
12. Hypercalcemia and elevated calcitriol in a maintenance dialysis patient with tuberculosis.
Felsenfeld AJ; Drezner MK; Llach F
Arch Intern Med; 1986 Oct; 146(10):1941-5. PubMed ID: 3767540
[TBL] [Abstract][Full Text] [Related]
13. Severe hypercalcemia in a patient treated for hypoparathyroidism with calcitriol.
De Sanctis V; Fiscina B; Ciccone S
Pediatr Endocrinol Rev; 2010 Jun; 7(4):363-5. PubMed ID: 20679997
[TBL] [Abstract][Full Text] [Related]
14. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
15. [Hypercalcemia in granulomatous diseases].
Peces R
Nefrologia; 2000; 20(5):393-5. PubMed ID: 11100658
[No Abstract] [Full Text] [Related]
16. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
[TBL] [Abstract][Full Text] [Related]
17. [Hypercalcemia in a female patient with chronic kidney failure secondary to sarcoidosis: a metabolic study of the calcium metabolism and bone histology].
Caravaca F; Cubero JJ; de Francisco AL; Arrobas M; Pizarro JL; Sánchez-Casado E
Med Clin (Barc); 1991 May; 96(17):659-61. PubMed ID: 2056801
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hypocalcemia caused by hypoparathyroidism or pseudohypoparathyroidism with domestic-made calcitriol: a prospective and self-controlled clinical trial.
Wang O; Xing XP; Meng XW; Xia WB; Li M; Jiang Y; Hu YY; Liu HC
Chin Med J (Engl); 2009 Feb; 122(3):279-83. PubMed ID: 19236804
[TBL] [Abstract][Full Text] [Related]
19. Hypercalcemia and suppressed PTH levels in a renal transplant patient infected with Pneumocystis carinii.
Aguirre AR; Balbo BE; Ianhez LE; da Costa MC; Andrade L
Ren Fail; 2007; 29(4):513-6. PubMed ID: 17497478
[TBL] [Abstract][Full Text] [Related]
20. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
